TGFb overexpression in human cancer cells has been shown to promote tumor progression. In the present study, we sought to determine whether sequestration of endogenous TGFb by the expression of a soluble TGFb type III receptor (sRIII), can reduce malignancy in human carcinoma cells and whether the tumor-suppressive activity of sRIII is associated with the inhibition of angiogenesis. Ectopic expression of sRIII signi®cantly inhibited the growth of tumors formed by human colon carcinoma HCT116 and breast carcinoma MDA-MB-435 cells in nude mice. It also reduced the metastatic potential of the MDA-MB-435 cells. Thus, endogenous TGFb appears to be necessary for the progression of these two carcinomas. Furthermore, when the tumor cells were mixed with Matrigel and embedded subcutaneously in nude mice, the blood volume in Matrigel plugs containing sRIII-expressing cells as indicated by hemoglobin levels was signi®cantly lower than that in Matrigel plugs containing the respective control cells. Blood vessel counts in paran sections of the Matrigel plugs containing sRIII-expressing cells were also signi®cantly lower than those in paran sections of the Matrigel plugs containing control cells. Treatment of human endothelial cells with a recombinant sRIII signi®cantly inhibited their ability to form a capillary web structure on Matrigel. These results for the ®rst time indicate that the sRIII-induced tumor suppression appears to be in part due to the inhibition of angiogenesis.
Introduction
Transforming growth factor beta (TGFb) belongs to a family of polypeptides that regulate cell proliferation, dierentiation, and migration through the activation of serine-threonine kinase receptors (Massague et al., 2000) . It is ubiquitously secreted by various types of cells in a latent form in which the prodomain of its precursor is non-covalently associated with the mature peptide. When activated, the mature TGFb can potently inhibit the proliferation of normal epithelial cells by blocking cell cycle progression from G1 to S phase. However, its growth inhibitory response is often lost or diminished in carcinoma cells due to inactivation or down regulation of TGFb receptors or its intracellular signaling mediators, or due to aberrant regulation of proteins that control cell cycle progression (Markowitz and Roberts, 1996; Massague et al., 2000) . On the other hand, increased expression of TGFb isoforms is often associated with development and progression of many types of carcinomas including human colon and breast carcinomas (Reiss, 1999; Norgaard et al., 1995) . Furthermore, overexpression of TGFb 1 was shown to stimulate tumor progression of human breast and colon cancer cells (Arteaga et al., 1993a; Ye et al., 1999) . One mechanism by which TGFb may stimulate tumor progression is apparently its angiogenic activity (Fajardo et al., 1996; Yang and Moses, 1990) . Overexpression of TGFb 1 in Chinese hamster ovary cells was shown to signi®cantly stimulate tumor growth and angiogenesis when inoculated into nude mice (Ueki et al., 1992) . As such, TGFb antagonists may oer a novel approach for cancer therapy.
TGFb type III receptor (RIII), also called betaglycan, is the major TGFb binding molecule on the cell surface and binds all three mammalian TGFb isoforms (TGFb 1 , b 2 and b 3 ) with high anity (Massague, 1990) . It is a membrane bound proteoglycan that is expressed in most cell types and tissues, and has been shown to generate, upon ectodomain shedding, a soluble form of the receptor (Andres et al., 1989; Lopez-Casillas et al., 1991) . While the membrane receptor enhances the TGFb eects, the soluble form is a potent TGFb neutralizing agent (Esparza-Lopez et al., 2001; Vilchis-Landeros et al., 2001) . In our previous studies, we have shown that expression of the extracellular domain of RIII in its soluble form (sRIII) in human breast cancer MDA-MB-231 cells can sequester endogenous TGFb isoforms and antagonize their activity. The expression of sRIII also suppressed the malignancy of the MDA-MB-231 cell in vivo (Bandyopadhyay et al., 1999) . Since MDA-MB-231 cells produce high levels of active TGFb isoforms and have an operational autocrine TGFb loop, the expression of sRIII presumably antagonized the action of tumor cell-produced TGFb in both tumor cells and stromal cells under the in vivo condition. To determine whether antagonizing TGFb's action in stromal cells alone is sucient to inhibit tumor growth, we examined, in the current study, the eect of sRIII expression on the in vivo growth of the human colon carcinoma HCT116 cell line, which is unresponsive to TGFb due to the mutational inactivation of the TGFb type II receptor gene (Wang et al., 1995) . Because TGFb has been implicated in tumor metastasis (Reiss, 1999) , we have also examined the eect of sRIII expression on the in vivo growth and metastasis of the human breast carcinoma MDA-MB-435 cell line which is highly metastatic when inoculated in orthotopic sites in nude mice (Price et al., 1990) . Our studies show that sRIII expression can inhibit the growth of tumors formed by HCT116 and MDA-MB-435 cells as well as metastasis by the MDA-MB-435 cell line, thus expanding our previous observation with respect to the versatility of the tumor suppressive activity of sRIII in various carcinoma models.
Since tumor growth and metastasis require angiogenesis (Folkman, 1995) and exogenous TGFb was shown to be angiogenic (Yang and Moses, 1990 ), we have also tested the hypothesis that the sRIII-mediated suppression of tumor cell proliferation and metastasis may be in part due to inhibition of angiogenesis. Our results indicate that the expression of sRIII can reduce the angiogenic potential of human carcinoma cells. Furthermore, sRIII directly inhibited the formation of a capillary web structure on Matrigel by human endothelial cells. Thus, for the ®rst time, both the in vivo and in vitro results in our study demonstrate that sRIII-induced tumor suppression appears to be at least in part due to the inhibition of angiogenesis.
Results
The expression of sRIII in HCT116 and MDA-MB-435 transfectants After stably transfecting an sRIII expression vector into HCT116 LDC3 and MDA-MB-435/GFP cells, we used an ELISA developed in our laboratory (Bandyopadhyay et al., 1999) to screen antibiotic-resistant clones for sRIII secretion into the conditioned medium. HCT116 clone C1.15 ( Figure 1a ) and three MDA-MB-435 clones (C1.5, C1.9, and C1.13) (Figure 1b ) were found to secrete appreciable amounts of sRIII into the conditioned medium in comparison with their respective controls (Neo Pool). To ascertain that the sRIII secreted by these clones can bind TGFb, we performed a receptor anity binding assay. Figure 2a ,b. These results suggest that the Figure 1 Quantitation of the secreted TGFb sRIII in the conditioned medium of (a) HCT116 Neo Pool, and sRIII Cl.15 and (b) MDA-MB-435 Neo Pool and sRIII Cl.5, Cl.9, and Cl.13. A 96-well immunoplate was coated at 48C overnight with known amounts of standard sRIII or with the media conditioned by the Neo Pool or sRIII clones. The sRIII adhering to the bottom of the wells was detected by an anti-human RIII antibody, which was recognized by protein A/G conjugated with horseradish peroxidase. The amount of sRIII is normalized by the cell number. The data are presented as means+s.e. of three determinations. N.D.=not detectable sRIII-transfected clones expressed and secreted high levels of functional sRIII protein.
We have previously shown that sRIII secreted by sRIII-transfected MDA-MB-231 cells can sequester active TGFb 1 and b 2 in their conditioned medium resulting in the loss of the growth inhibitory activity of the conditioned medium when applied to mink lung epithelial CCL64 cells, which are growth inhibited by TGFb (Bandyopadhyay et al., 1999) . HCT116 is known to secrete active TGFb 1 (Wang et al., 1995) . The expression of sRIII also signi®cantly (P50.05) attenuated the growth inhibitory activity of the medium conditioned by sRIII C1.15 on the growth of CCL64 cells, as shown in Figure 3a , con®rming the ecacy of the secreted-sRIII in antagonizing active TGFb 1 in the conditioned medium. MDA-MB-435 cells produce marginal levels of active TGFb 1 and TGFb 2 in the culture medium that are often undetectable with TGFb 1 or TGFb 2 ELISA although measurable levels of TGFb 1 were present in the extracts of its tumors formed in athymic nude mice (data not shown). As a result, the media conditioned by either Neo Pool or sRIII clones did not induce a growth inhibition in the CCL64 cells as compared with the control, which was not treated with any conditioned medium (Figure 3b ).
sRIII expression inhibited the growth of both human colon and breast cancer cells in vivo The expression of sRIII had no eect on in vitro growth of MDA-MB-435 and HCT116 cells under anchorage-dependent and independent conditions (data not shown) suggesting that sRIII itself did not aect the growth property of the cells. Since TGFb in Figure 3 The eect of the conditioned medium from HCT116 transfectants or MDA-MB-435 transfectants on the growth of CCL64 cells. Twenty-microliter medium conditioned (a) by HCT116 Neo Pool or sRIII Cl.15 or (b) by MDA-MB-435 Neo Pool or sRIII Cl.9 was added to newly plated CCL64 cells in a 96-well plate. The`Control' in (b) denotes no conditioned medium. After 5 days of incubation, the relative cell number in each well was determined by an MTT assay as described in Materials and methods and was expressed as absorbance. Each column represents the mean+s.e. from eight wells. * Indicates a signi®cant dierence (P50.05) from its Neo Pool the tumor environment has been shown to promote tumor growth and progression (Reiss, 1999) , we investigated whether antagonization of TGFb activity by the expression of sRIII can inhibit the growth of tumors formed by HCT116 and MDA-MB-435 cells in vivo. Exponentially growing cells of HCT116 Neo Pool and sRIII clone C1.15, were inoculated subcutaneously behind the anterior forelimb of 4-weekold female athymic nude mice. Tumors formed by Neo Pool cells grew consistently faster than the tumors formed by the sRIII clone ( Figure 4a ). The mean tumor volume of Neo Pool became signi®cantly (P50.05) larger than those of the sRIII clone 2 weeks after the inoculation. Similar growth inhibition by sRIII expression was observed in MDA-MB-435 cells in two separate experiments. Exponentially growing MDA-MB-435 Neo Pool and sRIII clones were inoculated into the orthotopic inguinal mammary fat pad area. In the ®rst experiment, the growth of the tumors formed by Neo Pool and sRIII C1.5 was compared ( Figure 4b ). In the second experiment, the growth of the tumors formed by Neo Pool was compared with the growth of the tumors formed by sRIII C1.9 or C1.13 ( Figure 4c ). Tumors formed by all three sRIII clones showed attenuated growth in comparison with those formed by the control cell. We were able to detect a high level of sRIII in the extracts of tumors formed by sRIII clones (Figure 4d ), suggesting that the sRIII-transfected cells can secrete sRIII in vivo as well as in vitro. Thus, sRIII expression ) of HCT116 Neo Pool and sRIII Cl.15 were inoculated subcutaneously behind the anterior forelimb of 4-week old athymic nude mice (a), whereas exponentially growing cells (10 6 ) of MDA-MB-435 Neo Pool and sRIII clones were inoculated into the inguinal mammary fat pad of 4-week-old female nude mice in two separate experiments (b and c). In all experiments, each cell type was inoculated at both sides of the respective site of a mouse. Tumors were measured externally in two dimensions with a caliper. Tumor volume was determined according to the equation: V=(L6W 2 )60.5, where L is the length and W is the width of a tumor. Each point represents the mean+s.e. of 10 measurements except for the last two measurements of the Neo Pool in (c), which represent the mean+s.e. of eight measurements. * Indicates a statistically signi®cant dierence (P40.05) between the Neo Pool and sRIII clones. (d) Quantitation of sRIII in the extracts of tumors formed by MDA-MB-435 Neo Pool, sRIII Cl.9 and sRIII Cl.13. sRIII from the tumor extracts was measured by a two antibody sandwich ELISA. An anti-human sRIII rabbit antibody was used as a capture antibody. sRIII captured by this antibody was detected with the ELISA described above for (a and b). The sRIII concentration was determined from a standard curve using a known amount of human sRIII and expressed as the average of duplicate measurements per milligram of total protein in the tumor extracts inhibited the in vivo growth of the two dierent carcinoma cell lines.
sRIII expression reduced spontaneous lung and axillary lymph node (ALN) metastasis of MDA-MB-435 cells
Because the MDA-MB-435 cells are highly metastatic when inoculated orthotopically (Price, 1996) and TGFb is implicated to enhance invasion and metastasis in some carcinomas (Reiss, 1999) , we also studied whether sRIII expression could inhibit the metastasis of the MDA-MB-435 cell in nude mice. To detect micrometastatic colonies in the lung and lymph nodes, we ectopically expressed the enhanced green¯uorescent protein in the MDA-MB-435 cell prior to the stable transfection of sRIII. This allowed us to visualize green metastatic colonies by examining whole lungs and axillary lymph nodes under an inverted¯uorescence microscope. The metastatic incidence, per cent of animals with lung or lymph node metastasis, in sRIII clone-inoculated mice was lower in both the lung and axillary lymph nodes than in Neo Pool-inoculated mice (Table 1 ). This observation is consistent with our previous studies in the human breast carcinoma MDA-MB-231 cells (Bandyopadhyay et al., 1999) . Thus, sRIII expression can abrogate the metastatic potential in these model systems.
sRIII expression reduced angiogenic potential of human breast cancer cells
Since angiogenesis is required for tumor growth and metastasis, we next examined the eect of sRIII expression on the angiogenic potential of MDA-MB-435 cells to elucidate the mechanism of the sRIIIinduced inhibition of tumor growth and metastasis. We performed a modi®ed Matrigel plug assay (Passaniti et al., 1992) in athymic nude mice. Matrigel, a solid gel of mouse basement membrane proteins derived from the EHS sarcoma (Kleinman et al., 1982) , has been shown to facilitate angiogenesis and tumor growth when mixed with angiogenic factors or tumor cells (Elenbaas et al., 2001; Fridman et al., 1991; Passaniti et al., 1992) . We mixed Matrigel with either Neo Pool or sRIII clones of MDA-MB-435 and injected the mixture subcutaneously into athymic nude mice. The mixture solidi®ed to form a plug upon injection. After 2 weeks, the Matrigel plugs were retrieved and were either ®xed for histological examination or extracted for hemoglobin assay. Examination of hematoxylin and eosin (H&E)-stained sections of the Matrigel plugs by a pathologist who had no knowledge of the experimental design revealed a large reduction of the number of blood vessels in the Matrigel plugs containing the sRIII clones in comparison with the control plugs. Figure 5a shows a typical high power ®eld (hpf) from a Neo Pool section with blood vessels containing red cells, whereas a section from an sRIII Cl.9 section showed no blood vessels. The reduction was found to be statistically signi®cant (P50.05) after the blood vessels were counted in 10 hpfs of each section from two Neo Pool plugs, one sRIII Cl.5 plug, and two sRIII Cl.9 plugs (Figure 5b ). The inhibition of blood vessel formation also resulted in a signi®cant (P50.05) reduction of blood volume in the sRIII Matrigel plugs as measured with hemoglobin assays (Figure 6a) . A similar reduction of blood volume was observed in Matrigel plugs containing sRIII-expressing MDA-MB-231 cells (Figure 6b ), which were previously shown to exhibit a signi®cantly lower tumorigenicity and metastatic potential than their control counterparts (Bandyopadhyay et al., 1999) . Thus, the inhibition of tumor growth and metastasis by sRIII expression appears to be at least in part due to the impairment of angiogenesis induced by the tumor cells.
Inhibition of capillary web formation by the treatment of endothelial cells with a recombinant sRIII
Formation of a capillary web structure by endothelial cells on Matrigel is widely used as an in vitro model of angiogenesis. To determine whether sRIII can directly impair the function of human endothelial cells, we studied the eect of the treatment with a human recombinant sRIII on the ability of normal human aortic endothelial cells (HAEC) to form a capillary web structure on Matrigel. When plated on Matrigel, HAECs rapidly align and form capillary tube-like web structures within 24 h. However, treatment with a recombinant human sRIII disrupted the web structure formation (Figure 7a ) as quanti®ed by a signi®cant (P50.05) reduction of the number of web junctions per microscopic ®eld at 2.0 mg/ml (approximately 20 nM) of sRIII (Figure 7b) . A web junction is de®ned as the intersection of at least three tubes. This result suggests that sRIII may inhibit angiogenesis by impairing the ability of endothelial cells to form blood vessels.
Discussion
Antagonization of TGFb activity by a TGF-b neutralizing antibody or sRIII expression was shown to inhibit the growth of tumors formed by human breast carcinoma MDA-MB-231 cells in nude mice (Arteaga et al., 1993b; Bandyopadhyay et al., 1999 (Oft et al., 1998; Yin et al., 1999) . Thus, it was not clear whether the tumor suppression by sRIII expression required the antagonization of autocrine TGFb signaling. Autocrine TGFb signaling in certain types of carcinoma is often lost during the progression of various types of cancer because of mutational inactivation of TGFb receptors or Smad proteins (Markowitz and Roberts, 1996; Massague et al., 2000) . Therefore, we sought to determine whether antagonization of TGFb's action in the tumor stroma through the expression of sRIII is sucient to inhibit tumor growth of human carcinoma cells without autocrine TGFb activity such as the human colon carcinoma HCT116 cell line. This cell line does not express the TGFb type II receptor, but produces a high level of active TGFb 1 (Wang et al., 1995) . The present study shows that sRIII expression in the HCT116 cell antagonized the growth inhibitory activity against mink lung epithelial cells by TGFb in HCT116 cell-conditioned medium and signi®cantly inhibited the growth of the cell line in vivo. Thus, TGFb's action in the tumor stroma appears to play a signi®cant role in promoting the in vivo growth of the HCT116 tumor, and antagonization of TGFb's action in the tumor stroma can cause tumor suppression. The MDA-MB-435 cell is one of a few human breast carcinoma cells that readily metastasize to lungs and lymph nodes when implanted orthotopically in nude mice (Price, 1996) . It secretes an abundant amount of latent TGFb 1 and TGFb 2 in tissue culture, but little of this TGFb is in an active form. However, active TGFb 6 cells of MDA-MB-435 Neo Pool, sRIII Cl.5, or sRIII Cl.9 and implanted subcutaneously at the abdominal midline of athymic nude mice at two sites per animal. After 2 weeks, one Matrigel plug harvested from each mouse was ®xed in formalin, embedded in paran and sectioned. Sections from two Neo Pool Matrigel plugs, one sRIII Cl.5 Matrigel plug, and two sRIII Cl.9 Matrigel plugs were stained with H&E and examined by light microscopy. (a) shows a typical microscopic ®eld (4006magni®cation) of a section from a Neo Pool Matrigel plug and a section from an sRIII Cl.9 Matrigel plug. Red cells in newly formed blood vessels are indicated with arrows. The total number of blood vessels from 10 high power ®elds in a section of each Matrigel plug was counted and presented as mean+s.e. in (b). The means of the blood vessel counts in all three sRIII Matrigel plugs were signi®cantly (P50.05) smaller than those in either of the two Neo Pool Matrigel plugs as indicated with an asterisk is readily detectable in the homogenate of MDA-MB-435 tumors formed in nude mice (Bandyopadhyay and Sun, unpublished data) . To determine whether the active TGFb in the tumor contributes to its growth and metastasis, we also investigated the eect of sRIII expression on the growth and metastatic potential of the MDA-MB-435 cell line in our current study. All three sRIII clones showed retarded growth in vivo when compared with the control cell line. The in vivo growth of Cl.5 was apparently inhibited most even though it secreted a less amount of sRIII into the conditioned medium than Cl.9 and Cl.13 did. This could be due to clonal variation among the three sRIII clones since they were obtained from a heterogeneous parental line. On the other hand, we have previously observed changes of in vivo growth rate for a given sRIII clone in dierent experiments even though the sRIII clone always grew slower than the control (Bandyopadhyay et al., 1999) . Thus, since the tumor growth study of Cl.5 was performed in a separate experiment from that of Cl.9 and Cl.13, our experimental design appears inadequate for the elucidation of the relationship between the sRIII expression level and the in vivo tumor growth rate. What we can conclude is that the expression of sRIII inhibited the malignancy of the MDA-MB-435 cell.
Previously, we have shown that sRIII expression signi®cantly inhibited tumor growth and lung metastasis by MDA-MB-231 cells (Bandyopadhyay et al., 1999) . However, because of its weak metastatic potential, the lung metastasis of the MDA-MB-231 cell is usually not observed until the primary xenograft reaches 1 cm 3 in volume. Thus, it was not clear to us whether sRIII inhibited the lung metastasis of the MDA-MB-231 cell directly, or did so indirectly 6 tumor cells or bFGF (1 mg/0.5 ml) were prepared as described in Figure 5 and in Materials and methods. Two weeks after implantation, they were harvested and homogenized. The hemoglobin content in the homogenate as well as in the systemic blood was measured and used to calculate blood volume in each Matrigel plug. (a) Shows the mean and standard error of blood volume of three Matrigel plugs containing MDA-MB-435 Neo Pool, sRIII Cl.5, and sRIII Cl.9 or bFGF, whereas (b) shows the mean and standard error of blood volume of three Matrigel plugs containing MDA-MB-231 Neo Pool, sRIII Cl.34, and sRIII Cl.41. sRIII expression signi®cantly (P50.05) reduced blood volume in both model systems as indicated with an asterisk Figure 7 Dose dependent inhibition of the ability of HAECs to form a capillary web structure by a recombinant sRIII. Exponentially growing HAECs were plated on the top of solidi®ed Matrigel in a 24-well plate at 30 000 cells/well. A recombinant human sRIII was added to the cells at 0, 0.5 and 2 mg/ml after plating. The capillary tube-like web structure was visualized under 406magni®cation and captured with a digital camera (a). The web junctions, de®ned as an intersection of at least three tubes, were counted in four randomly captured microscopic ®elds for each treatment and expressed as mean+s.e. (b). The asterisk indicates a signi®cant (P50.05) reduction of web junctions by sRIII treatment through the inhibition of the growth of its primary tumor. In contrast to the MDA-MB-231 cells, we obtained greater than 50% lung and axillary lymph node metastatic incidence when the volume of the primary xenograft formed by the control MDA-MB-435 cell reached 0.2 cm 3 within 6 weeks after inoculation in our preliminary studies (data not shown). Thus, the reduced metastatic incidence in sRIII Cl.9 and Cl.13 appears to be due to a direct inhibition of metastasis by sRIII since the average volume of the primary tumors formed by both clones was 0.2 cm 3 or greater at the termination of the experiment. Our results are consistent with published observations that TGFb treatment or overexpression respectively stimulated the metastasis of a mammary adenocarcinoma or Chinese hamster ovary cells (Ueki et al., 1993; Welch et al., 1990) . Taken together, our current study extended our previous observations into carcinoma models with dierent phenotypes of TGFb signaling and malignancy demonstrating the versatility of the tumor suppressive activity of sRIII.
Several earlier studies have shown that exogenous TGFb is angiogenic in vivo. For example, overexpression of TGFb 1 in Chinese hamster ovary cells signi®cantly stimulated tumor growth and angiogenesis when they were inoculated into nude mice (Ueki et al., 1992) . Administration of TGFb 1 was shown to cause formation of granulation tissue in newborn mice (Roberts et al., 1986) , as well as to induce blood vessel formation in chicken chorioallantoic membrane (Yang and Moses, 1990 ) and in polyvinyl alcohol foam discs placed subcutaneously in mice (Fajardo et al., 1996) . However, whether endogenous TGFb produced by tumor and stromal cells in a tumor environment is also angiogenic remained to be elucidated. Since angiogenesis is a limiting step for the growth and metastasis of solid tumors (Hanahan and Folkman, 1996) , we investigated whether the inhibition of the in vivo growth and metastasis of MDA-MB-435 and MDA-MB-231 cells by sRIII expression also involved the inhibition of angiogenesis. We utilized an in vivo angiogenesis model by embedding Matrigel plugs containing control or sRIII-expressing cancer cells to examine whether the sequestration of extracellular TGFb by the secreted sRIII can inhibit cancer cellinduced angiogenesis. Both the blood vessel counts and the hemoglobin content in the Matrigel plugs containing sRIII-expressing MDA-MB-435 cells were signi®-cantly reduced when compared with the plugs containing the control cells. Similar results were also observed in sRIII-expressing MDA-MB-231 cells. Our study suggests that endogenous TGFb plays a signi®cant role in angiogenesis and that sRIII may have potential therapeutic utility as an angiogenic inhibitor.
Since angiogenesis involves the sprouting, proliferation, migration, and dierentiation of endothelial cells (Folkman, 1972; Herbst et al., 1988) , we have begun to investigate how antagonizing TGFb signaling may aect the function of endothelial cells. When endothelial cells are cultured on Matrigel, they rapidly align and form a hollow tube-like web structure. This process is thought to mimic the process by which endothelial cells form capillaries in vivo. Therefore, as an initial step of our investigation, we examined whether TGFb signaling is necessary for the formation of capillary tube-like web structures by endothelial cells. Treatment of normal human aortic endothelial cells with a recombinant sRIII, which was shown to be a potent TGFb neutralizing agent in vitro (VilchisLanderos et al., 2001), showed a dose-dependent inhibition of their ability to form a capillary web structure on Matrigel. This is consistent with an earlier study showing that exogenous TGFb 1 induced tubular structure formation when endothelial cells were embedded in collagen gel (Madri et al., 1988) . Whereas further studies are needed to elucidate the molecular pathways that mediate TGFb's angiogenic activity, our results suggest that the inhibition of tumor cell-induced angiogenesis in vivo by sRIII expression may be in part due to a direct impairment of endothelial cells' ability to form capillaries.
In summary, our current and previous studies (Bandyopadhyay et al., 1999) demonstrate that the expression of TGFb sRIII can suppress the malignancy of human carcinomas with dierent malignant phenotypes. The inhibition of tumor growth and metastasis appears to be, in part, due to the inhibition of angiogenesis by sRIII. Our results suggest that endogenous TGFb in late stage carcinomas can promote their progression regardless of their TGFb signaling status.
Materials and methods

Cell lines
Human breast cancer cell line MDA-MB-231 and mink lung epithelial cell line CCL64 were originally obtained from the American Type Tissue Culture Collection. Human breast cancer line MDA-MB-435 was a generous gift from Dr. Janet Price. These cell lines were cultured in McCoy's 5A medium supplemented with pyruvate, vitamins, amino acids, antibiotics, and 10% fetal bovine serum (FBS) (Sun and . Human colon cancer cell line HCT116 was established in vitro from a primary tumor and maintained in a serum-free medium as described previously (Boyd et al., 1988; Brattain et al., 1984) . Working cultures were maintained at 378C in a humidi®ed incubator with 5% CO 2 . HCT116 limiting dilution clones were obtained by plating parental cells into 96-well culture plates at 0.5 cell/well. One of the limiting dilution clones called LDC3 was previously found to be unresponsive to TGFb due to a homozygous mutation of its type II receptor gene (Wang et al., 1995) and was used for the expression of sRIII in the current study. The MDA-MB-435 cell line was previously shown to be metastatic in nude mice (Price, 1996) . To determine the eect of sRIII expression on early metastatic potential of the cell, we stably transfected the enhanced green¯uorescent protein (GFP) expression plasmid, pEGFP-N1 (Clontech Laboratories, Inc.), into MDA-MB-435 cells and obtained a pool of GFP-expressing cells called MDA-MB-435/GFP. The expression of GFP allowed us to detect micrometastatic colonies in the whole lungs and lymph nodes under an inverted¯uorescence microscope as others have reported (Chishima et al., 1997) .
Vector construction and transfection
The expression vector containing the cDNA encoding the extracellular domain of human TGFb RIII was constructed and stably transfected into HCT116 LDC3 and MDA-MB-435/GFP as described earlier (Bandyopadhyay et al., 1999) . The control cells were transfected with the empty vector. Selection of stable transfectants was accomplished by adding Geneticin (G418 sulfate; Life Technologies, Inc.) to the culture medium at 600 mg/ml. G418-resistant control clones were pooled and designated as Neo Pool. sRIII-transfected clones were individually ring-cloned and expanded for screening of sRIII expression.
Measurement of sRIII in the conditioned medium and tumor extract
The secretion of sRIII into the conditioned medium by sRIIItransfected clones was detected by an ELISA using an anti-RIII antibody (R&D Systems) and Protein A/G-HRP conjugate (Pierce) as described previously (Bandyopadhyay et al., 1999) . For the determination of sRIII level in the xenograft tumors, tumor tissues were extracted as described previously (Joseph et al., 1995) with some modi®cations. Brie¯y, frozen tumor tissues were weighed, pulverized while frozen in liquid nitrogen, and extracted with ice-cold extraction buer, 20 mM Tris, pH 7.5, 0.5 M NaCl, 0.1 mM phenylmethylsulphonyl¯uoride, at a ratio of 6 ml extraction buer to 1 g of tissue. The precipitate was re-extracted with the same buer containing 1 M NaCl. The pooled supernatants were dialyzed against PBS and stored at 7808C. Protein concentrations of the extracts were determined using the BioRad Coomassie blue dye-binding microassay (BioRad, Richmond, VA, USA). sRIII levels in the same amount of tumor extract protein from dierent samples were determined by a sandwich ELISA developed in our laboratory. An antibody against the human sRIII was raised in rabbits by the injection of a puri®ed baculoviral recombinant human sRIII (Montiel and Lopez-Casillas, unpublished data) following standard immunization protocols (Harlow and Lane, 1988) . The antibody was pre-coated at 1 : 5000 dilution to the bottom of a 96-well immunoplate (Dynatech Laboratories, Inc) as the capture antibody. The wells were washed with PBS containing 0.5% Tween-20 and blocked with 1% BSA. Standards and tumor extracts were added into the wells and incubated for 2 h at 378C. The bound sRIII was detected after subsequent incubation with an anti-human sRIII goat antibody (R&D Systems, 1 : 500 dilution), an anti-goat IgG conjugated with horseradish peroxidase (Pierce, 1 : 30 000 dilution), and a horseradish peroxidase substrate mixture containing H 2 O 2 and ophenylenediamine dihydrochloride. The ®nal reaction was stopped with the addition of 6N H 2 SO 4 , and the absorbance was determined with a microplate reader at 492 nm. The sRIII level in the tumor extract was determined from a standard curve using known amounts of a recombinant human sRIII (R&D Systems).
Receptor cross-linking
The TGFb binding activity of the secreted sRIII was con®rmed with receptor cross-linking assays as described previously (Bandyopadhyay et al., 1999) . Brie¯y, [
125 I]TGFb 1 (200 pM) was incubated with 100 ml of the conditioned medium from the transfected clones to allow the formation of the [
125 I]TGFb 1 -sRIII complex. The complex was crosslinked with disuccinimidyl suberate and visualized after SDS ± PAGE and autoradiography .
Measurement of growth inhibitory activity of media conditioned by control cells and sRIII-transfectants
A bioassay was used to measure growth inhibitory activity of the media conditioned by control and sRIII-transfected cells in the growth of the mink lung epithelial CCL64 cells as described previously . Brie¯y, the control and sRIII-transfected cells were cultured in six-well plates until they reached 100% con¯uence. The medium was replenished with a serum-free medium and conditioned for 72 h. The media were then collected, and the cell number in each well was counted with a hemocytometer. The conditioned media (20 ml) from duplicate wells for each cell type were added to CCL64 cells after they were plated in a 96-well plate. After 5 days of incubation, the relative cell number in each well was obtained with MTT assay (Carmichael et al., 1987) and expressed as optical density.
Tumorigenicity and metastasis
Exponentially growing cultures of human breast cancer MDA-MB-435/GFP control and sRIII transfectants were inoculated subcutaneously into both sides of the inguinal mammary fat pad area of 4-week-old female athymic nude mice (Harlan Sprague Dawley, Inc.) at 10 6 cells per site in two dierent sets of experiments. Exponentially growing cultures of human colon cancer HCT116 control and a sRIII transfectant were inoculated subcutaneously behind the anterior forelimb of 4-week-old female athymic nude mice (Harlan Sprague Dawley, Inc.) at 5610 6 cells per site. Each xenograft was monitored weekly by externally measuring tumors in two dimensions using a caliper. Xenograft volume (V) was determined by the following equation: V=(L6W 2 )60.5, where L is the length and W the width of a xenograft.
To determine the metastatic potential of MDA-MB-435/ GFP control and sRIII transfectants, xenograft-bearing animals were sacri®ced after the growth study and both lung and axillary lymph nodes were removed during autopsy and examined to detect any disseminated tumor cell metastasis. The green metastatic cancer cell colonies, if any, were identi®ed using a NIKON¯uorescence microscope (TE-200) with a 206objective (2006magni®cation).
Matrigel plug assay
Matrigel plug assays for the determination of angiogenesis were performed as described previously with modi®cations (Passaniti et al., 1992) . Matrigel (Becton Dickinson Labware, Bedford, MA, USA) was thawed overnight at 48C and mixed with either cell suspension (3610 6 cells/0.5 ml Matrigel) or bFGF (R&D Systems, 1 mg/0.5 ml Matrigel). The mixture was implanted subcutaneously in two sites at the abdominal midline of the 4-to 5-week-old female nude mice (Harlan Sprague Dawley, Inc.). The mixture solidi®ed to form a plug upon implantation. After 14 days, the mice were anesthetized and subsequently euthanatized after the removal of the Matrigel plugs and blood through cardiac puncture. One plug from each mouse was ®xed in 10% buered formalin (Fisher Scienti®c) and embedded in paran. Sections of 5 mm were cut from the embedded plugs and stained with H&E. Sections were examined by light microscopy under 4006magni®cation, and the number of blood vessels from 10 hpfs were counted and averaged. All sections were coded and observed by a pathologist who was blinded for the study protocol. The other plug was weighed and pulverized in liquid nitrogen with a pestle and a mortar. The pulverized tissue was homogenized in 0.9% NaCl solution with a Wheaton Dounce Tissue Grinder. The supernatant of the homogenate was analysed for hemoglobin content using a hemoglobin assay kit (Sigma) following the manufacturer's instruction. Blood hemoglobin content was also measured and the results were expressed as blood volume per unit weight of Matrigel.
Endothelial tube assay
Matrigel was added to a 24-well plate at 320 ml per well and allowed to polymerize at 378C for 1 h. A suspension of 30 000 normal human aortic endothelial cells (HAEC) in EGM medium (Clonetics, MD, USA) was added to a Matrigel-coated well. The cells were treated with dierent concentrations of a recombinant human sRIII (R&D Systems) and incubated for 24 h at 378C. The capillary web structure was viewed with a Nikon (T-200) microscope under 406magni®cation and captured with an Olympus MagnaFire digital camera. The web junctions, de®ned as an intersection of three or more tubes, were counted in each microscopic ®eld.
